It’s rare for a company to highlight its burgeoning competition. But Illumina did just that in a court filing last month.
The San Diego-based company — which makes DNA sequencers that power everything from consumer genetic tests to precision drug development — commands about 80 percent of the market. The Federal Trade Commission in 2021 cited Illumina’s market share in challenging the company’s acquisition of Grail, a cancer testing company.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.
